We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Combination inhibition of the renin-angiotensin system: is more better?
- Authors
Krause, Michelle W.; Fonseca, Vivian A.; Shah, Sudhir V.
- Abstract
Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers are considered the standard of care for treatment of cardiovascular disease and chronic kidney disease. Combination therapy with both angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers effectively inhibits the renin-angiotensin system as well as potentiates the vasodilatory effects of bradykinin. It has been advocated that this dual blockade approach theoretically should result in improved clinical outcomes in both cardiovascular disease and chronic kidney disease. Clinical trial evidence for the use of combination therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in cardiovascular disease has provided conflicting results in hypertension, congestive heart failure, and ischemic heart disease. Clinical trial evidence to support combination therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chronic kidney disease has largely been based on proteinuria reduction as a surrogate marker for clinically meaningful outcomes. Recent large-scale randomized clinical trials have not been able to validate protection in halting progression in chronic kidney disease with a dual blockade approach. This review serves as an appraisal on the clinical evidence of combination angiotensin-converting enzyme inhibition and angiotensin II receptor blockade in both cardiovascular disease and chronic kidney disease.
- Subjects
RENIN-angiotensin system; ACE inhibitors; ANGIOTENSINS; CARDIOVASCULAR diseases; CHRONIC kidney failure
- Publication
Kidney International, 2011, Vol 80, Issue 3, p245
- ISSN
0085-2538
- Publication type
Article
- DOI
10.1038/ki.2011.142